What is the recommended treatment regimen for enteric fever?

Treatment of Enteric Fever

Primary Recommendation

For enteric fever treatment, use azithromycin as first-line therapy in regions with fluoroquinolone resistance (particularly South Asia), ceftriaxone for severe cases or extensively drug-resistant strains, and reserve fluoroquinolones only for areas with documented susceptibility. 1, 2, 3

Treatment Algorithm Based on Resistance Patterns and Geography

First-Line Treatment Selection

Azithromycin is the preferred oral agent for uncomplicated enteric fever, particularly in South Asia where fluoroquinolone resistance is widespread 1, 2, 3:

• Azithromycin demonstrates lower clinical failure rates (OR 0.48,95% CI 0.26-0.89) and shorter hospital stays (-1.04 days) compared to fluoroquinolones 1
• Azithromycin shows lower relapse rates (OR 0.09,95% CI 0.01-0.70) compared to ceftriaxone 1
• In nalidixic acid-resistant strains, azithromycin achieves 96% clinical cure versus 81% with ofloxacin 4
• Azithromycin provides faster fever clearance (135 hours vs 174 hours) in fluoroquinolone-resistant cases 4

Second-Line and Severe Disease Treatment

Ceftriaxone is the treatment of choice for:

• Severe or complicated enteric fever requiring hospitalization 1, 5, 6
• Extensively drug-resistant (XDR) typhoid strains from Pakistan 2, 3
• Treatment failures with oral agents 1, 5
• All organisms remain susceptible to ceftriaxone throughout recent surveillance periods (2005-2014) 7

Ceftriaxone demonstrates equivalent or superior outcomes:

• May result in decreased clinical failure compared to azithromycin (RR 0.42,95% CI 0.11-1.57) 5
• Provides shorter fever clearance time compared to azithromycin (mean difference -0.52 days) 5

Fluoroquinolone Use: Geographic Restrictions

Fluoroquinolones should be avoided in South Asia due to widespread resistance 2, 7, 3:

• Minimum inhibitory concentrations (MICs) against fluoroquinolones have risen significantly since 2005 and correlate with increasing fever clearance times 7
• In children with nalidixic acid-resistant strains, older fluoroquinolones increase clinical failures compared to azithromycin (OR 2.67,95% CI 1.16-6.11) 1
• Ciprofloxacin should be specifically avoided for cases originating from South Asia 3

Fluoroquinolones may still be considered in regions with documented susceptibility:

• Gatifloxacin shows equivalent or better outcomes than other antimicrobials in susceptible strains 7
• Fluoroquinolones reduce clinical relapse versus chloramphenicol (OR 0.14,95% CI 0.04-0.50) 8

Extensively Drug-Resistant (XDR) Typhoid

For XDR strains (particularly from Pakistan):

• Azithromycin and/or meropenem are required 2
• Combination therapy targeting both intracellular and extracellular bacteria is under investigation 2
• Ceftriaxone remains effective when susceptibility is confirmed 2, 7

Critical Pitfalls to Avoid

Do not rely on WHO 2012 guidelines recommending fluoroquinolones as first-line 1:

• These recommendations are outdated given current resistance patterns 7
• The policy should change based on evidence showing rising fluoroquinolone MICs and treatment failures 7

Do not use older first-line antibiotics (chloramphenicol, sulfamethoxazole-trimethoprim, amoxicillin, ampicillin) as they carry higher risk of clinical failure 1

Do not use cefixime as first-line oral therapy:

• Cefixime shows increased clinical failure (RR 13.39,95% CI 3.24-55.39), microbiological failure (RR 4.07), and relapse (RR 4.45) compared to fluoroquinolones 5
• Cefixime results in longer fever clearance time (mean difference 1.74 days) 5

Treatment Duration and Monitoring

Standard treatment courses:

• Azithromycin: 5-7 days at 20 mg/kg/day (maximum 1g daily) 4
• Ceftriaxone: 7-14 days for severe cases 5, 6
• No significant differences demonstrated between different fluoroquinolone treatment durations 8

Monitor for complications requiring intensive care:

• Myocardial dysfunction, encephalopathy, hemophagocytic lymphohistiocytosis may require adjunctive dexamethasone and IVIG 6